We work with our customers on a basis of open communication and trust. Our extensive drug discovery experience is shown in our efficient workflows and the necessary flexibility to provide our customers with the best confirmed leads for their target.

6 projects found

COILED open innovation centre launched

COILED, Center for Open Innovation in LEad Discovery, is a new public-private open innovation centre focused on the early phase of pharmaceutical drug development. Pivot Park Screening Centre is one of the open innovation centre's partners.

View project

Exciting new hits for a novel drug target involved in depression and pain unveiled in the European Lead Factory project Committed to strengthening the antibiotic arsenal

An exciting innovative target involved in these debilitating conditions was discovered by Dr Patrick McHugh, University of Huddersfield. “We don’t have the facilities to carry out large scale screening campaigns to fully assess the possibilities of our findings.

View project

NCardia partners with Pivot Park Screening Centre to offer ultra High Throughput Screening for Cardiovascular drug discovery services

NCardia and Pivot Park Screening Centre announced a collaboration to improve NCardia’s cardiovascular drug discovery service offerings and to expand Pivot Park Screening Centre’s knowledge about new and innovative assay technologies used to accelerate drug discoveries.

View project

ZeGlobalTox – a rapid and reliable preclinical screening tool

The zebrafish (Danio rerio) is a tropical fish with a genetic structure surprisingly similar to ours. However, they’ve become a popular model organism only relatively recently.

View project

NTRC publishes high-throughput screening assay for IDO1 and TDO in Journal of Biomolecular Screening

Immunotherapy is one of the recent advances in cancer treatment. Cancer immunotherapy makes use of the body’s immune system to help fight cancer.

View project

Committed to strengthening the antibiotic arsenal

Dr Monika Schütz and Jonas Malte Schweers at the Tübingen University Hospital and the Interfaculty Institute of Microbiology and Infection Medicine Tübingen (IMIT) are studying gut-derived pathogens in the framework of the German Centre for Infection Research (DZIF). They have identified several target proteins involved e.g. in facilitating the attachment of bacteria to the human host cells, a mechanism that is key for virulence.

View project
  • 1